Business

Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025

SOPHIA ANTIPOLIS, France, May 12, 2025--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will attend two major health conferences and present posters

articleMedian TechnologiesMay 12, 20256/company/median-technologies/news/median-technologies-to-present-scientific-posters-on-eyonisr-lcs-in-two-major-health-conferences-in-north-america-in-may-2025-1
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025

About this update from Median Technologies

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/d1479f22eb6d8a628fdf2a3becea7b48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ERAsdh5bBDstKq2W5ShgzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d1479f22eb6d8a628fdf2a3becea7b48","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/v7L8E6F0BKx.P4BOlvHmGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d1479f22eb6d8a628fdf2a3becea7b48","width":1200,"height":446}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Projected economic benefits of using AI-powered detection/diagnostic Software as a Medical Device, like eyonis® LCS, will be presented at ISPOR 2025, the annual conference of the leading professional society for health economics and outcomes research","length":250,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Positive eyonis® LCS’ REALITY pivotal data to be presented at American Thoracic Society (ATS) 2025 International Conference","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The eyonis® team will be hosting interested parties at booth #1662 during ATS 2025","length":82,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":455,"olType":false},{"type":"text","content":"SOPHIA ANTIPOLIS, France, May 12, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will attend two major health conferences and present posters on its Software as a Medical Device (SaMD) eyonis® LCS, for Lung Cancer Screening.","length":546,"tagName":"p"},{"type":"text","content":"The eyonis® LCS SaMD is an AI-powered Software as a Medical Device (SaMD) to detect and diagnose (CADe/CADx) lung ca...

More updates from Median Technologies

American Thoracic SocietyLung Cancer ScreeningInternational ConferenceTechnologiesMedical DeviceLCSlung cancerATSISPORSaMDSoftware